Quanterix and Tempus Integrate AI-Guided Alzheimer’s Blood Testing

Lucent Diagnostics, a diagnostics brand owned by Quanterix, has partnered with Tempus to integrate blood-based Alzheimer’s biomarker testing into clinical workflows used by neurologists. The companies said the collaboration will allow physicians using Tempus Next to identify patients who may benefit from biomarker testing and order LucentAD Complete directly through existing electronic health record (EHR) integrations.

LucentAD Complete is a blood-based Alzheimer’s assessment test that measures biomarkers associated with amyloid pathology, neurodegeneration, and neuroinflammation. According to Lucent Diagnostics, the test combines measurements including p-Tau217, Aβ42/40, GFAP, and NfL into a multi-analyte algorithmic assessment.

Tempus said its Tempus Next platform uses AI-enabled care pathway intelligence to identify care gaps and surface guideline-based clinical insights at the point of care. The company has been expanding the platform across multiple disease areas as part of a broader push into AI-driven diagnostics and clinical workflow infrastructure.

Read more: Tempus CEO Eric Lefkofsky Says ‘This Could Be as Big as Apple’ in Healthcare AI

Quanterix said more than 7 million Americans are living with Alzheimer’s disease, while many patients remain unevaluated for treatment eligibility. The companies said the partnership is intended to support earlier identification and assessment through routine neurological workflows.

FDA Momentum Around Blood-Based Alzheimer’s Diagnostics

The collaboration comes as blood-based Alzheimer’s diagnostics move closer to broader clinical adoption in the United States. In May 2025, the U.S. Food and Drug Administration (FDA) cleared the first blood test intended to aid Alzheimer’s diagnosis, marking a regulatory milestone for the category.

Quanterix separately announced in January that it submitted a 510(k) application to the FDA for LucentAD Complete.

The company has also expanded commercialization efforts around the platform. In late 2025, the Centers for Medicare and Medicaid Services (CMS) established a reimbursement rate of $897 for LucentAD Complete, according to Quanterix’s fourth-quarter earnings release.

Healthcare companies have increasingly focused on integrating AI systems directly into physician workflows rather than using standalone diagnostic platforms. That includes care-gap identification, patient stratification, and biomarker-guided treatment pathways. Similar efforts around AI agents in healthcare workflows have expanded across clinical operations and diagnostics infrastructure.

Quanterix Expands Biomarker Platform Through Acquisitions

The Tempus collaboration follows Quanterix’s broader expansion into integrated biomarker analysis. In July 2025, the company completed its acquisition of Akoya Biosciences, which it said created “the first integrated platform capable of measuring biomarkers across the blood and tissue continuum.”

Masoud Toloue, CEO of Quanterix, said at the time that the acquisition would expand the company’s addressable market from $1 billion to $5 billion and strengthen its position across neurology, oncology, and immunology markets.

The broader healthcare market has seen growing investment in multimodal AI systems that combine clinical, molecular, and biomarker data to guide treatment decisions and disease detection.

Tempus and Quanterix are positioning the collaboration around operational integration rather than standalone testing, with the companies emphasizing physician workflow access, guideline-driven identification, and direct ordering inside existing healthcare systems.